Ono Pharmaceutical, an Osaka, Japan-based bio/pharmaceutical company, has completed its $2.4-billion acquisition of Deciphera Pharmaceuticals, a Waltham, Massachusetts-based bio/pharmaceutical company. The acquisition was announced in May 2024. 

The acquisition adds to Ono’s oncology operations and provides the company with commercial operations in the US and Europe. Deciphera’s key commercial product is Qinlock (ripretinib), which is approved in over 40 countries and marketed globally, including in the US, Europe, and China, for the treatment of fourth-line gastrointestinal stromal tumors, a type of cancer that begins in the digestive system. A key late-stage drug candidate is vimseltinib, now in Phase III development, for treating patients with tenosynovial giant cell tumors, a group of rare tumors that cause the synovium, bursae, or tendon sheaths to thicken and overgrow and damage the surrounding tissue and structures of affected limbs.   

Ono acquired all outstanding shares of the common stock of Deciphera Pharmaceuticals for $25.60 per share (total amount of approximately $2.4 billion) net to the seller in cash, without interest thereon and less any applicable withholding taxes, through its wholly owned subsidiary, Topaz Merger Sub, established in the State of Delaware, US, solely for this transaction.  

Source: Ono Pharmaceutical